Phase II Neoadjuvant ER+/PgR + Arimidex +/- Iressa study
Study identifier:1839IL/0223
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
Phase II, placebo controlled, parallel group, double blind, randomised, multicentre trial comparing the Anastrozole (Arimidex®) placebo combination to the Anastrozole - ZD1839 (Iressa™) combination as neoadjuvant treatment in postmenopausal women with stage I-IIIB breast cancer and Oestrogen Receptor (ER) and/or Progesterone (PgR) positive tumours
Medical condition
Breast Cancer
Phase
Phase 2
Healthy volunteers
No
Study drug
Anastrazole, Gefitinib
Sex
Female
Actual Enrollment
185
Study type
Interventional
Age
N/A
Date
Study Start Date: 01 Jan 2004
Primary Completion Date: -
Study Completion Date: 01 Nov 2005
Study design
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verification:
Verified 01 Apr 2009 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
AstraZeneca Iressa Medical Sciences Director
AstraZeneca
